News & Events
News & Events
2017 Institut Pasteur Korea Open Call: Joint Research Projects for Free RNAi Screening
2017-06-02
-To discover best-in-class and first-in-class drugs
Pangyo, Gyeonggi, 2 Jun, 2017 | Institut Pasteur Korea (IPK, CEO: Dr. Wang-Shick Ryu) announces an open call on IPK RNAi Screening to link outstanding research result to industrialization. This free service includes access to IPK’s technology, skills and the know-how necessary to translate a project at the basic research level into commercial applicability.
IPK’s ‘Phenomic Technologies*’, next-generation drug discovery technology platforms, combine advances from the latest bio-imaging techniques with high throughput screening technologies, to enable the real-time observation and analysis of cellular disease models in a high throughput mode. IPK can also identify previously unknown target genes associated with diseases and find new compounds that can serve as leads for innovative drug discovery.
Candidates chosen to collaborate on research projects will be provided with assay development support and a pilot RNAi screen at no cost. IPK screening specialist will work closely with Grantees to help discover and identify novel drug targets that will be developed into best-in-class and first-in-class drugs.
.jpg)
The open call process has a 2 step review process with applications due by 23 Jun, 2017. For more info about applicant eligibility, the evaluation process, application form, etc., visit www.ip-korea.org or contact the RTM team (031-8018-8032 | RTV-DIV@ip-korea.org).
About Institut Pasteur Korea
Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and an economic growth engine that contributes to Korea's scientific intellectual and technical resources. IPK has four core missions of public interest; 1) Research, combining front line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases, 2) Education, offering a wide range of programming to nurture the development of the next generation of scientists and health professionals, 3) Public Health, working in collaboration with national and international health authorities, and 4) Translation of biomedical discoveries to improve health via technology transfer and industrial partnerships.
IPK is a member of the Institut Pasteur International Network (Network). As a hub institution, IPK plays a key role in the Network, serving as a bridge between Korea and global bio-pharma science, expanding Korea's R&D base collaborative research projects with global alliances
The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science, ICT and Future Planning (MSIP). IPK also has a great supporter in the Gyeonggi Provincial government (2005 – 2015 : Block funding | 2016 – Present : drug discovery co-resarch fund for pharm industries).
Pangyo, Gyeonggi, 2 Jun, 2017 | Institut Pasteur Korea (IPK, CEO: Dr. Wang-Shick Ryu) announces an open call on IPK RNAi Screening to link outstanding research result to industrialization. This free service includes access to IPK’s technology, skills and the know-how necessary to translate a project at the basic research level into commercial applicability.
IPK’s ‘Phenomic Technologies*’, next-generation drug discovery technology platforms, combine advances from the latest bio-imaging techniques with high throughput screening technologies, to enable the real-time observation and analysis of cellular disease models in a high throughput mode. IPK can also identify previously unknown target genes associated with diseases and find new compounds that can serve as leads for innovative drug discovery.
Candidates chosen to collaborate on research projects will be provided with assay development support and a pilot RNAi screen at no cost. IPK screening specialist will work closely with Grantees to help discover and identify novel drug targets that will be developed into best-in-class and first-in-class drugs.
The open call process has a 2 step review process with applications due by 23 Jun, 2017. For more info about applicant eligibility, the evaluation process, application form, etc., visit www.ip-korea.org or contact the RTM team (031-8018-8032 | RTV-DIV@ip-korea.org).
*Phenomic Technologies: next-generation drug discovery technology platforms
Ø PhenomicScreen™ - a visual– and cell-based high throughput/ high content target-free screening platform. It quantifies biological events in living cells and allows the cells themselves to identify the most effective drug targets from millions of complex molecular interactions.
Ø PhenomicID™ - assesses the impact of genes in the cell by turning off each gene, one by one. The entire human genome and focused gene sets are available for screening using cell imaging technology to identify physiologically-relevant molecular pathways and targets involved in the development of the phenotype of the diseases under study.
About Institut Pasteur Korea
Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and an economic growth engine that contributes to Korea's scientific intellectual and technical resources. IPK has four core missions of public interest; 1) Research, combining front line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases, 2) Education, offering a wide range of programming to nurture the development of the next generation of scientists and health professionals, 3) Public Health, working in collaboration with national and international health authorities, and 4) Translation of biomedical discoveries to improve health via technology transfer and industrial partnerships.
IPK is a member of the Institut Pasteur International Network (Network). As a hub institution, IPK plays a key role in the Network, serving as a bridge between Korea and global bio-pharma science, expanding Korea's R&D base collaborative research projects with global alliances
The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology (KIST), with support from the Ministry of Science, ICT and Future Planning (MSIP). IPK also has a great supporter in the Gyeonggi Provincial government (2005 – 2015 : Block funding | 2016 – Present : drug discovery co-resarch fund for pharm industries).